Effectiveness of Valerian on insomnia: a meta-analysis of randomized placebo-controlled trials
Effectiveness of Valerian on insomnia: a meta-analysis of randomized placebo-controlled trials
Fernández-San-Martín et al., 2010 | Sleep Med | Meta Analysis
Citation
Fernández-San-Martín Maria Isabel, Masa-Font Roser, ... Flores-Mateo Gemma. Effectiveness of Valerian on insomnia: a meta-analysis of randomized placebo-controlled trials. Sleep Med. 2010-Jun;11(6):505-11. doi:10.1016/j.sleep.2009.12.009
Abstract
BACKGROUND: Insomnia is an often seen primary health care problem. Valerian might be an alternative treatment with fewer secondary effects. The aim of this study is to evaluate its effectiveness on insomnia through a meta-analysis of published literature. METHODS: Search for randomized clinical trials (RCTs) of Valerian preparations compared with a placebo on Medline, the Cochrane Library, Embase and Biosis. OUTCOMES: sleep-quality improvement (SQ, yes/no), sleep-quality improvement quantified through visual analogical scales (SQS) and the latency time (LT) in minutes until getting to sleep. Three meta-analyses were carried out using inverse-variance weighted random effects models. Heterogeneity was determined with the Q-statistic and was explored through a sub-groups analysis. Publication bias was evaluated using the funnel plot. RESULTS: Eighteen RCTs were selected; eight had a score of 5 on Jadad's scale. The mean differences in LT between the Valerian and placebo treatment groups was 0.70 min (95% CI, -3.44 to 4.83); the standardized mean differences between the groups measured with SQS was -0.02 (95% CI, -0.35 to 0.31); treatment with Valerian showed a relative risk of SQ of 1.37 (95% CI, 1.05-1.78) compared with the placebo group. There was heterogeneity in the three meta-analyses, but it diminished in the sub groups analysis. No publication bias was detected. CONCLUSION: The qualitative dichotomous results suggest that valerian would be effective for a subjective improvement of insomnia, although its effectiveness has not been demonstrated with quantitative or objective measurements. We recommend future investigations oriented toward improving insomnia with other more promising treatments.
Key Findings
Eighteen RCTs were selected; eight had a score of 5 on Jadad's scale. The mean differences in LT between the Valerian and placebo treatment groups was 0.70 min (95% CI, -3.44 to 4.83); the standardized mean differences between the groups measured with SQS was -0.02 (95% CI, -0.35 to 0.31); treatment with Valerian showed a relative risk of SQ of 1.37 (95% CI, 1.05-1.78) compared with the placebo group. There was heterogeneity in the three meta-analyses, but it diminished in the sub groups analysi
Outcomes Measured
- Requires manual extraction
Population
| Field | Value |
|---|---|
| Population | See abstract |
| Sample Size | See abstract |
| Age Range | See abstract |
| Condition | insomnia |
MeSH Terms
- Humans
- Pain Measurement
- Phytotherapy
- Plant Extracts
- Randomized Controlled Trials as Topic
- Sleep Initiation and Maintenance Disorders
- Treatment Outcome
- Valerian
Evidence Classification
- Level: Meta Analysis
- Publication Types: Journal Article, Meta-Analysis
- Vertical: valerian-sleep
Provenance
- PMID: 20347389
- DOI: 10.1016/j.sleep.2009.12.009
- PMCID: Not in PMC
- Verified: 2026-04-09 via PubMed E-utilities API
Source extracted via PubMed E-utilities API on 2026-04-09